Results 21 to 30 of about 5,281 (192)

Development of a Trivalent Seasonal Influenza Vaccine Using Long α-Helix-Mediated Trimeric HA1 Proteins Produced in Baculovirus-Insect Cell System. [PDF]

MedComm (2020)
MedComm, Volume 7, Issue 8, August 2026.
Guo N, Xu Z, Chen X, Han X, Xue T, Yan J, Huang Q.   +6 more
europepmc   +2 more sources

Identification of Mannose-Capped-Arabinomannan 101-mer as a Potential Influenza Virus Vaccine Adjuvant. [PDF]

Adv Sci (Weinh)
Well‐defined and synthetic mannose‐capped arabinomannan 101‐mer from Mycobacterium tuberculosis cell wall was identified as a potent influenza vaccine adjuvant, boosting the antibody response, realizing full protection and showing excellent safety. ABSTRACT Many natural bacterial components as adjuvants can activate the host immune system, but the ...
Zhang YF, Xu R, Luo J, Ma Y, Xiao G, Liu Y.   +5 more
europepmc   +2 more sources

Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis [PDF]

European Journal of Immunology, 2001
The mechanisms associated with the immunostimulatory activity of vaccine adjuvants are still poorly understood. We have undertaken a study to determine whether antigen-presenting cell trafficking is modified by administration of the submicron emulsion adjuvant MF59.
M, Dupuis, K, Denis-Mize, A, LaBarbara, W, Peters, I F, Charo, D M, McDonald, G, Ott   +6 more
openaire   +2 more sources

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine [PDF]

New England Journal of Medicine, 2009
The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority.We conducted a single-center study, involving 176 adults, 18 to 50 years of age, to test the monovalent influenza A/California/2009 (H1N1) surface-antigen vaccine, in both MF59-adjuvanted ...
Clark, Tristan, Pareek, Manish, Höschler, Katja, Dillon, Helen, Nicholson, Karl G, Groth, Nicola, Stephenson, Iain   +6 more
openaire   +3 more sources

ارزیابی عملکرد ب ث ژ به همراه نانو سلنیوم سنتتیک به عنوان تقویت‌کننده در فرمولاسیون واکسن کاندید علیه استافیلوکوکوس اورئوس بر پایه‌ی IsdE در مدل موشی [PDF]

مجله دانشکده پزشکی اصفهان
مقاله پژوهشیمقدمه: : استافیلوکوکوس اورئوس باعث ایجاد انواع عفونت‌های بیمارستانی و افزایش مرگ و میر ناشی از آن می‌شود. واکسیناسیون، یک روش مناسب برای مقابله با این عفونت‌ها است. آهن، نقش مهمی در پاتوژنز باکتری دارد.
فاطمه خسروانی پور, ستاره حقیقت, محمد حسین یزدی, سیدمهدی حسن زاده   +3 more
doaj   +1 more source

Cross-herpesvirus immunity of the cytomegalovirus gB/MF59 vaccine response. [PDF]

NPJ Vaccines
Abstract Vaccination against human cytomegalovirus (HCMV) to protect transplant recipients and prevent congenital infection remains highest priority. Follow-up analyses of a vaccine directed against the fusion protein glycoprotein B (gB/MF59) identified a vaccine-specific response (AD-6) that correlated with protection.
Lankina A, Hargreaves A, Lui WT, Kropff B, Wei A, Breuer J, White RE, Thomas M, Griffiths PD, Reeves MB.   +9 more
europepmc   +4 more sources

Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

Clinical and Developmental Immunology, 2010
We studied whether MF59-adjuvanted influenza vaccine improves immunity against drifted influenza strains in institutionalised elderly with underling chronic health conditions.
Vincenzo Baldo, Tatjana Baldovin, Michele Pellegrini, Gabriele Angiolelli, Silvia Majori, Annarosa Floreani, Marta Cecilia Busana, Chiara Bertoncello, Renzo Trivello   +8 more
doaj   +1 more source

Influenza-Impfstoff mit MF59-Adjuvans [PDF]

pharma-kritik, 2008
In vielen Studien vermochte dieser mit einem Squalen-haltigen Adjuvans kombinierte Impfstoff eine stärkere Immunantwort  – aber auch mehr unerwünschte Wirkungen – als andere Impfstoffe auszulösen. Ob sich daraus klinische Vorteile ergeben, ist bisher nicht adäquat dokumentiert.nzentwicklung zu erwarten ist. 
openaire   +1 more source

MF59^®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis [PDF]

Influenza and Other Respiratory Viruses, 2008
Abstract  Influenza is a major cause of worldwide morbidity and mortality through frequent seasonal epidemics and infrequent pandemics. Morbidity and mortality rates from seasonal influenza are highest in the most frail, such as the elderly, those with underlying chronic conditions and very young children. Antigenic mismatch between strains recommended
Banzhoff, Angelika, Pellegrini, Michele, Del Giudice, Giuseppe, Fragapane, Elena, Groth, Nicola, Podda, Audino   +5 more
openaire   +2 more sources

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

Human Vaccines & Immunotherapeutics, 2018
The poor immune response elicited by trivalent influenza vaccines (TIVs) in children can be enhanced by the addition of adjuvants. This observer-blind, randomized Phase III trial assessed the immunogenicity and safety of the MF59-adjuvanted trivalent ...
Aurelio Cruz-Valdez, Gabriel Valdez-Zapata, Sanjay S. Patel, Flavia V. Castelli, Marcia G. Garcia, Wim T. Jansen, Ashwani Kumar Arora, Esther Heijnen   +7 more
doaj   +1 more source